1Sledge GW,Neuberg D,Bernardo P.Phase III trial of doxorubicin,paclitaxel,and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer:an intergroup trial (E1193) [J].J Clin Oncol,2003,21(4):588
2Gebbia V,Blasi L,Borsellino N,et al.Paclitaxel and epidoxorubicin or doxorubicin versus cyclophosphamide and epidoxorubicin as first-line chemotherapy for metastatic breast carcinoma:a randomised phase II study[J].Anticancer Res,2003,23(1B):765
3Horwitz SB,Cohen D,Rao S,et al.Taxel:mechanisms of action and resistance[J].J Nail Cancer Inst,1993,15:15
4Friedrichs K,Holzel F,Janicke F.Combination of taxanes and anthracyclines in first-line chemotherapy of metastatic breast cancer:an interim report[J].Eur J Cancer,2002,38(13):1730
5Hsu C,Huang CS,Chao TY,et al.Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naive patients with locally advanced or metastatic breast carcinoma[J].Cancer,2002,95(10):2044
6Zimatore M,Danova M,Vassallo E,et al.Weekly taxanes in metastatic breast cancer (review) [J].Oncol Rep,2002,9(5):1047
7Blum JI, et al.Multicenter, Phase Ⅱ study of capecitabine in taxane -pretreated metastatic breast carcinoma patients.Cancer, 2001, 92: 1759- 1768.
